If you or your loved one has relapsed Chronic Lymphocytic Leukemia (#CLL), an important new clinical trial may be an option.
New cancer treatment guidelines say repeated genetic testing is important to making the right treatment decisions and improving outcomes in patients with CLL. As part of the study, participants will receive genetic testing at no cost. This trial is testing whether adding an investigational medication (ublituximab) to ibrutinib (Imbruvica®), an FDA-approved treatment, improves outcomes for high-risk CLL patients.
If you are interested, the full study details and eligibility criteria are listed here.
This trial is testing the safety and effectiveness of an investigational drug for the treatment of Cushing's Syndrome. Under the supervision of qualified physicians, cortisol levels and symptoms of Cushing’s Syndrome will be closely followed along with any signs of side effects.
More about the study:
The study drug (COR-003) is administered by tablets.
There will be 90 participants in this trial
There is no placebo used in the trial
If you are interested, please find the full study details and eligibility criteria listed here.
be at least 18 years old
have been diagnosed with endogenous Cushing's Syndrome by a medical professional (not caused by the use of steroid medications)
Participants must not:
have been treated with radiation for Cushing's Syndrome in the past 4 years
be currently using weight loss medication
have been diagnosed with uncontrolled hypertension, some forms of cancer, adrenal carcinoma, Hepatitis B / C, or HIV